Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTURE: Cabozantinib in MET exon 14 altered NSCLC after resistance to MET inhibitors
jRCT2051240082Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Response rate. Started Aug 2024; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240082.